Navigation Links
Zerenex (ferric citrate) long-term Phase 3 study results published in JASN
Date:7/24/2014

New York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

This Phase 3 study was a multicenter, randomized, open-label trial in 441 ESRD patients on hemodialysis or peritoneal dialysis designed to determine the safety and efficacy of Zerenex as a treatment to reduce serum phosphorus as well as raise iron stores and reduce intravenous (IV) iron and erythropoietin-stimulating agents (ESA) usage.

Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Using a sequential gatekeeping strategy for the key pre-defined secondary end-points, Zerenex also demonstrated statistically significant increases in serum ferritin and transferrin saturation (TSAT), and significant reductions in the use of IV iron and ESAs, versus an active control of Renvela (sevelamer carbonate) and/or Phoslo (calcium acetate) over the 52-week Active Control Period of the study. In addition, mean hemoglobin levels were higher in subjects treated with Zerenex as compared to subjects treated with active control.

"Zerenex effectively reduces serum phosphorus levels within the KDOQI range (3.5 mg/dL to 5.5 mg/dL) while having the additional patient benefits of increasing iron stores and decreasing the need for IV iron and ESAs, while maintaining hemoglobin levels," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medici
'/>"/>

Contact: Amy Sullivan
amy.sullivan@keryx.com
617-466-3447
Keryx Biopharmaceuticals, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. The Holistic Sanctuary Issues Response to The Irish Times About the Risks of Long-term Methadone Use
3. Circassias Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction
4. Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
7. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
8. Genomatica, Inc., Award-Winning Industrial Biotechnology Pioneer, Selects Alexandria Real Estate Equities, Inc. for Long-Term, Mission-Critical R&D Facility and Corporate Headquarters
9. Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
10. Resolve Initiates Phase 2 Clinical Study in SLE
11. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... 2015 Biovista Inc. freut ... von 2015 bekanntgeben zu können. Hierbei handelt es ... Biovista unterstützt mit seiner Möglichkeit der ... anderer Krankheiten als denen, für die ein Medikament ... sein Team bei der Wylder Nation Foundation bei ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Hanover Insurance Group, Inc. (NYSE: THG ... insurance products nationwide, announced today that it has ... equipment, orthotics and prosthetics sector -- which are ... (Logo: http://photos.prnewswire.com/prnh/20051031/NEM023LOGO) The new ...
... Tengion, Inc (NASDAQ: TNGN ), a leader in ... Chief Financial Officer of Tengion, will present at the upcoming ... 13, 2011, at 1:35 pm EDT. A ... of Events" in the Investors section of the Company,s website ...
... Sept. 7, 2011 MedWaves, AveCure™ microwave coagulation-ablation ... (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely ... over one-thousand patients worldwide, including lesions in bone, ... to bring its technology to treat lesions in ...
Cached Biology Technology:The Hanover Expands Innovative Solution for the Durable Medical Equipment, Orthotics and Prosthetics Market 2The Hanover Expands Innovative Solution for the Durable Medical Equipment, Orthotics and Prosthetics Market 3Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... options and pressures influence nearly every part of children,s ... a special supplement of the American Journal of Preventative ... at the University of Michigan, reveal that, in most ... soft drink bottling companies give students easy access to ...
... is one of two gene-hunting facilities in the nation ... to rigorously sort out how such environmental factors as ... genetic makeup to affect their risk for disorders as ... The Johns Hopkins Center for Inherited Disease ...
... HARBOR, N.Y. -- The first manual specifically geared ... Cold Spring Harbor Laboratory Press ( www.cshlpress.com ). ... from bioinformatics, technology, statistics, and biology, to provide a ... that are feasible for a wide range of laboratories. ...
Cached Biology News:Studies: Children obese due to a host of unhealthy pressures 2Studies: Children obese due to a host of unhealthy pressures 3Studies: Children obese due to a host of unhealthy pressures 4'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 2'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 3New book presents successful strategies for probing genetic variation 2New book presents successful strategies for probing genetic variation 3
... The pACHLT-A-BFP Baculovirus Transfer Vector is a derivative ... the gene for blue fluorescent protein (BFP), followed ... site (MCS).,Foreign genes are expressed as BFP-6xHis fusion ... restriction enzyme,sites (EcoR I, Stu I, Sac I, ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... pLivSelect is a direct antibiotic-based selection ... solely on colony survival, eliminating the need ... inexpensive process provides close to 100% accuracy ... ideal platform for robot colony picking. This ...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Biology Products: